Compare Bristol-Myers Squibb Co (BMY) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Packaging Corporation of America — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Packaging Corporation of America trades at $225.8 (market cap $20.11B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.8× Packaging Corporation of America's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | PKG | |
|---|---|---|
Market Cap | $116.30B | $20.11B |
Sector | Health | Technology |
52-Week High | $62.37 | $246.31 |
52-Week Low | $42.60 | $191.41 |
Enterprise Value | $152.24B | $23.94B |
Dividend Yield | 4.42% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Packaging Corporation of America (PKG) trades at $225.86, down 1.27% on the day, with a bearish technical signal but oversold RSI near support at $225. Recent Q1 2026 earnings beat expectations with EPS of $2.40, though revenue growth is modest and net income margins are projected to decline. The company announced a 20% dividend increase to $6.00 annually, signaling confidence in cash flow. Analyst consensus is mixed with a Hold rating but a $254.43 price target implies 13% upside from current levels.
Outlook is cautiously optimistic given valuation support from dividends and earnings beats, but risks include margin pressure from input costs and a negative net cash flow trend. The stock's investment case hinges on execution against Q2 guidance of $2.33 EPS and management's ability to navigate cost inflation. Near-term price action will be driven by the July 23 earnings call results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
